Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The antibody was designed and developed at Abzena’s Cambridge, UK,
Tourmaline is now an indirect wholly owned subsidiary of Novartis
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Subscribe To Our Newsletter & Stay Updated